Drug Search Results
More Filters [+]

TQB-3823

Alternative Names: tqb-3823, tqb 3823, tqb3823, TQB3823 tablets
Latest Update: 2023-11-03
Latest Update Note: Clinical Trial Update

Product Description

TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.

Mechanisms of Action: PARP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TQB-3823

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TQB3823-I-01

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2025-02-01

39%

Recent News Events

Date

Type

Title